Evidence map›Paper›PMID 24925970›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2014

Phosphodiesterase type 4 blockade prevents platelet-mediated neutrophil recruitment at the site of vascular injury.

Licia Totani, Antonio Piccoli, Giuseppe Dell'Elba, Amore Concetta, Angelomaria Di Santo, Nicola Martelli, Lorenzo Federico, Zehra Pamuklar, Susan S Smyth, Virgilio Evangelista

Open access · bronzeAbstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Platelets: Context-Dependent Vascular Protectors or Mediators of Disease.Arteriosclerosis, thrombosis, and vascular biology · 2015
    Review
  10. Platelet-neutrophil interactions under thromboinflammatory conditions.Cellular and molecular life sciences : CMLS · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Licia TotaniFrom the Department of Translational Pharmacology, Laboratory of Vascular Biology and Pharmacology, Fondazione Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy (L.T., A.P., G.D., A.C., A.D.S., N.M., V.E.); Division of Cardiovascular Medicine, The Gill Heart Institute, Lexington, KY (L.F., Z.P., S.S.S.); and VA Medical Center, Lexington, KY (S.S.S.).
Antonio PiccoliFrom the Department of Translational Pharmacology, Laboratory of Vascular Biology and Pharmacology, Fondazione Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy (L.T., A.P., G.D., A.C., A.D.S., N.M., V.E.); Division of Cardiovascular Medicine, The Gill Heart Institute, Lexington, KY (L.F., Z.P., S.S.S.); and VA Medical Center, Lexington, KY (S.S.S.).
Giuseppe Dell'ElbaFrom the Department of Translational Pharmacology, Laboratory of Vascular Biology and Pharmacology, Fondazione Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy (L.T., A.P., G.D., A.C., A.D.S., N.M., V.E.); Division of Cardiovascular Medicine, The Gill Heart Institute, Lexington, KY (L.F., Z.P., S.S.S.); and VA Medical Center, Lexington, KY (S.S.S.).
Amore ConcettaFrom the Department of Translational Pharmacology, Laboratory of Vascular Biology and Pharmacology, Fondazione Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy (L.T., A.P., G.D., A.C., A.D.S., N.M., V.E.); Division of Cardiovascular Medicine, The Gill Heart Institute, Lexington, KY (L.F., Z.P., S.S.S.); and VA Medical Center, Lexington, KY (S.S.S.).
Angelomaria Di SantoFrom the Department of Translational Pharmacology, Laboratory of Vascular Biology and Pharmacology, Fondazione Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy (L.T., A.P., G.D., A.C., A.D.S., N.M., V.E.); Division of Cardiovascular Medicine, The Gill Heart Institute, Lexington, KY (L.F., Z.P., S.S.S.); and VA Medical Center, Lexington, KY (S.S.S.).
Nicola MartelliFrom the Department of Translational Pharmacology, Laboratory of Vascular Biology and Pharmacology, Fondazione Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy (L.T., A.P., G.D., A.C., A.D.S., N.M., V.E.); Division of Cardiovascular Medicine, The Gill Heart Institute, Lexington, KY (L.F., Z.P., S.S.S.); and VA Medical Center, Lexington, KY (S.S.S.).
Lorenzo FedericoFrom the Department of Translational Pharmacology, Laboratory of Vascular Biology and Pharmacology, Fondazione Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy (L.T., A.P., G.D., A.C., A.D.S., N.M., V.E.); Division of Cardiovascular Medicine, The Gill Heart Institute, Lexington, KY (L.F., Z.P., S.S.S.); and VA Medical Center, Lexington, KY (S.S.S.).
Zehra PamuklarFrom the Department of Translational Pharmacology, Laboratory of Vascular Biology and Pharmacology, Fondazione Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy (L.T., A.P., G.D., A.C., A.D.S., N.M., V.E.); Division of Cardiovascular Medicine, The Gill Heart Institute, Lexington, KY (L.F., Z.P., S.S.S.); and VA Medical Center, Lexington, KY (S.S.S.).
Susan S SmythFrom the Department of Translational Pharmacology, Laboratory of Vascular Biology and Pharmacology, Fondazione Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy (L.T., A.P., G.D., A.C., A.D.S., N.M., V.E.); Division of Cardiovascular Medicine, The Gill Heart Institute, Lexington, KY (L.F., Z.P., S.S.S.); and VA Medical Center, Lexington, KY (S.S.S.).
Virgilio EvangelistaFrom the Department of Translational Pharmacology, Laboratory of Vascular Biology and Pharmacology, Fondazione Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy (L.T., A.P., G.D., A.C., A.D.S., N.M., V.E.); Division of Cardiovascular Medicine, The Gill Heart Institute, Lexington, KY (L.F., Z.P., S.S.S.); and VA Medical Center, Lexington, KY (S.S.S.). evangelista@negrisud.it.
Hypertension Institute · US

Funding

Kentucky Center for Clinical and Translational ScienceUL1TR000117 · NCATS · UNIVERSITY OF KENTUCKY · PI KERN, PHILIP A · 2012 to 2015
$13.3M
The Platelet-Leukocyte Switch in Vascular DiseaseP01HL080166 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JACOBSON, KENNETH A · 2006 to 2010
$6.7M
KENTUCKY CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCEUL1RR033173 · NCRR · UNIVERSITY OF KENTUCKY · PI KERN, PHILIP A · 2011 to 2011
$3.5M
Lysolipid Signaling in Cardovascular DiseaseR01HL078663 · NHLBI · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI SMYTH, SUSAN S. · 2004 to 2013
$2.5M
NCATS NIH HHS UL1 TR000117NCRR NIH HHS UL1 RR033173NCRR NIH HHS UL1RR033173NHLBI NIH HHS HL078663NHLBI NIH HHS HL080166NHLBI NIH HHS P01 HL080166NHLBI NIH HHS R01 HL078663
6 · The paper itself

Abstract

objectivePlatelet-neutrophil interactions play a key role in cardiovascular disease and inflammatory processes. Src family kinases mediate P-selectin glycoprotein ligand-1-Mac-1 cross talk necessary for firm platelet-neutrophil adhesion. Because Src family kinase activity can be regulated by cAMP-dependent pathways, in this work, we evaluated the role of phosphodiesterases in the signaling events that are required to sustain platelet-neutrophil interactions and neutrophil recruitment at the site of vascular injury. APPROACH AND

resultsIn neutrophils exposed to P-selectin, selective phosphodiesterase 4 (PDE4) inhibition prevented Src family kinase-mediated phosphorylation of the proline-rich tyrosine kinase 2 on Tyr579/Tyr580. The effects of PDE4 inhibition required protein kinase A, likely through protein kinase A-mediated activation of COOH-terminal Src kinase, a major negative regulator of Src family kinases. PDE4, but not other phosphodiesterase inhibitors, reduced platelet-neutrophil conjugates as well as neutrophil firm adhesion on spread platelets under flow conditions. The effect of PDE4 inhibition on neutrophil adhesion was primarily mediated by downregulation of P-selectin-induced activation of Mac-1. In a murine model of endovascular injury, selective inhibition of PDE4 significantly reduced neutrophil recruitment at the site of vascular damage.

conclusionsThis study identifies PDE4 as a central node in the signaling network that mediates platelet-neutrophil adhesion and suggests that pharmacological inhibition of PDE4 may represent a novel therapeutic avenue for the treatment of cardiovascular disease.

Indexed as

4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinoneAnimalsBlood PlateletsCyclic AMP-Dependent Protein KinasesDisease Models, AnimalFemoral ArteryFocal Adhesion Kinase 2HumansMacrophage-1 AntigenMiceMice, KnockoutNeutrophil InfiltrationNeutrophilsPhosphodiesterase 4 InhibitorsPhosphorylationPlatelet Adhesiveness4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinoneCyclic AMP-Dependent Protein KinasesFocal Adhesion Kinase 2Macrophage-1 AntigenPhosphodiesterase 4 InhibitorsP-SelectinPTK2B protein, humanRolipramSELP protein, humansrc-Family Kinasesneutrophilsphosphodiesterase 4 inhibitorsplatelets

Identifiers

PMID24925970
PMCPMC4117992
OpenAlexW2133734124

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.